About this trial
In this study, the investigators will use a wearable device capable of performing this bedside assessment to evaluate the incidence of visual field loss in post-stroke patients. Furthermore, for those with visual field loss, the investigators will investigate whether integrating multisensory audio-visual rehabilitation into the standard physical rehabilitation protocol can help improve visual field loss compared to standard rehabilitation alone.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 to 99 years with stroke (excluding isolated cerebellar, brainstem, or spinal cord strokes), admitted to Neurology in IRCCS San Martino Polyclinic Hospital with the ability to understand and sign the informed consent for study participation.
Mobility of at least one upper limb.
Disqualifiers
Presence of cognitive impairment (with an MMSE score less than 24), which limits the understanding of the informed consent or the ability to perform the test.
Difficulty moving both upper limbs.
Presence of ocular comorbidity that could affect visual field assessment before stroke.
Presence of fluent aphasia, neglect, or head and gaze deviation.
Trial design
Parallel
Treatments tested in this trial
Early multisensory audio-visual stimulation training
Other interventionMultisensory audio-visual stimulation training (using the device AV DESK Linari Medical) will last four weeks. Through audiovisual stimuli produced by the Av-Desk Flexi device, patients undergo a brain cell training program that compensates for blind spots in their visual field. The recipes regulating the combinations of stimuli are provided daily, under the supervision of a physician, where the data processing unit manages the data from the stimuli provided to the patient, their response to said stimuli, and monitors their position. The follow up visual field test will detect whether early intervention with multisensory audio-visual stimuli can improve visual field loss
Early visual field test
Diagnostic testVisual field assessment with wearable devices (PalmScan VF2000) performed at the bedside in post-stroke patients who met the inclusion criteria during their stay in the neurology hospital unit, as soon as they were stabilized. Standard 120-point visual field tests will be performed on the left and right eyes separately, with the following quantification parameters: test duration, fixation losses, false positives, false negatives, points seen, points not seen, relative defects. Patients with a monocular residual perimetric defect of less than 106 points seen out of 124 (equal to 85% of the stimuli presented) and in any case with a defect greater than 12 points if presented in a single quadrant, will be selected for the clinical trial and invited to repeat the same visual field evaluation, using the same wearable devices in the 2-months follow-up.
Treatment groups
Trial outcomes
Primary outcomes
Recovery rate in patients who receive training with multisensory audio-visual stimuli
Visual field test (120pt neuro programme) per each eye at follow up compared with the screening test. The functional rate will be in percentage (on 124 stimuli) adding 1 integer for seen points, 0.5 for relative points
Spontaneous recovery rate of visual field defects after stroke
Visual field test (120pt neuro programme) per each eye at follow up compared with the screening test. The functional rate will be in percentage (on 124 stimuli) adding 1 integer for seen points, 0.5 for relative points
Secondary outcomes
Incidence of visual field defects in post-stroke patients
Number of patients with visual field defects, will be compared with literature and retrospective study on clinical records of the hospital neurology clinic.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fondazione David Chiossone - Impresa Sociale
Lead sponsor
IRCCS AOU San Martino, Genova, Italy
Collaborator
This trial is not recruiting at the moment. You can still explore other options: